Clinical trials · New York
Aggression clinical trials in New York
We’re tracking 13 recruiting aggression studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Commack, New YorkAges Any age - NCT07091279RecruitingPhase 2
Test of Propranolol for Severe Behaviors in Autism
This study tests a medication called propranolol to see if it can reduce aggression and other severe behaviors in adolescents and adults with autism. It might be an option if you have frequent and serious challenging behaviors that other treatments haven't helped.
White Plains, New YorkAges 12–40 - NCT07434479Recruiting
Virtual reality mindfulness for aggression in schizophrenia
This study tests whether a virtual reality mindfulness program can help people with schizophrenia who have problems with impulsive aggression. You would use a VR headset for relaxation exercises and answer questions about your mood and behavior.
White Plains, New YorkAges 18–64 - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Buffalo, New YorkAges 18 years+ - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
New York, New YorkAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Buffalo, New YorkAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
New York, New YorkAges 18 years+ - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Brooklyn, New YorkAges 60 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Buffalo, New YorkAges 18 years+ - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New York, New YorkAges 18 years+ - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Albany, New YorkAges 18 years+ - NCT07156565RecruitingPhase 1
Targeted radiation therapy for advanced sarcoma
This trial tests a new radioactive drug for people with advanced soft tissue sarcoma that has come back or not responded to prior treatment. The drug targets a protein found on sarcoma cells to deliver radiation directly to the tumor.
New York, New YorkAges 18 years+
Aggression trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting aggression studies listed above.
- Memorial Sloan Kettering Cancer Center · 4 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Memorial Sloan Kettering Nassau · 2 studies
- Montefiore Medical Center · 2 studies
- Roswell Park Cancer Institute · 2 studies
- Weill Cornell Medicine · 2 studies
- Center for Autism and the Developing Brain
- Columbia University Irving Medical Center
What taking part in a aggression study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Aggression trials in other states
Common questions
- Are there aggression clinical trials in New York?
- Yes. We're currently tracking 13 recruiting aggression studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a aggression study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New aggression studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.